An Peng, Dang Hui-Min, Shi Xing-Min, Ye Bing-Yu, Wu Xi-Li
Department of Integrated Chinese Traditional and Western Medicine, the Second Affiliated Hospital, Medical School of Xi׳an Jiaotong University, Shaanxi Province Key TCM Department of Nephrology, Xi׳an 710004, China.
Medical School of Xi׳an Jiaotong University, Xi׳an 710061, China.
J Ethnopharmacol. 2014 Aug 8;155(1):277-84. doi: 10.1016/j.jep.2014.05.019. Epub 2014 May 27.
Although the exact mechanism(s) underlying acupuncture remain unknown, acupuncture and acupuncture-like somatic nerve stimulation have been used to treat different kidney diseases and several complications related to them.The aim of this preliminary study was to assess the effectiveness of acupuncture on glomerulonephritis (GN) according to the theory of "Wind-hided renal collaterals" previously proposed.
We used a New Zealand white rabbit model of cationized bovine serum albumin (cBSA)-induced glomerulonephritis and then administered them metoprolol, irbesartan or acupuncture to evaluate the effectiveness of acupuncture treatment and preliminarily explore its potential mechanism.
After immunization, our results showed that compared to the cBSA+MET and cBSA+IRB medication groups, "Qufeng Tongluo" significantly lowered parameters of renal function and improved podocyte injury in the 3rd, 6th and 8th weeks of treatment. Moreover, acupuncture increased the protein expression of phosphorylated ERK1/2.
Our study suggests that a potential mechanism by which acupuncture has an antihypertensive effect and can significantly halt deteriorating renal function due to cBSA GN might be mediated by inhibiting the Erk1/2 MAPK pathway to reduce renal sympathetic nerve activity (RSNA).
尽管针灸的确切作用机制尚不清楚,但针灸及类似针刺的躯体神经刺激已被用于治疗不同的肾脏疾病及其相关并发症。本初步研究的目的是根据先前提出的“风伏肾络”理论,评估针灸治疗肾小球肾炎(GN)的有效性。
我们采用阳离子化牛血清白蛋白(cBSA)诱导的新西兰白兔肾小球肾炎模型,然后给予它们美托洛尔、厄贝沙坦或进行针灸,以评估针灸治疗的有效性并初步探索其潜在机制。
免疫后,我们的结果显示,与cBSA+MET和美托洛尔药物治疗组相比,“祛风通络”在治疗的第3、6和8周显著降低了肾功能参数,改善了足细胞损伤。此外,针灸增加了磷酸化ERK1/2的蛋白表达。
我们的研究表明,针灸具有降压作用,并能显著阻止由于cBSA GN导致的肾功能恶化,其潜在机制可能是通过抑制Erk1/2 MAPK途径来降低肾交感神经活性(RSNA)。